CAR-T 细胞治疗后血细胞减少：63 例复发/难治性 B 细胞非霍奇金淋巴瘤患者分析

The present study aimed to determine the clinical characteristics of cytopenia in patients with relapsed and refractory B-cell non-Hodgkin lymphoma (B-NHL) who were treated with chimeric antigen receptor T-cell (CAR-T) therapy.

Thus, a total of 63 patients with relapsed and refractory B-NHL who underwent CAR-T therapy between March 2017 and October 2021 were retrospectively selected for analysis. Neutropenia, anemia and thrombocytopenia at grade 3 occurred in 48 (76. 19%), 16 (25. 39%) and 15 (23.

80%) cases, respectively. The results of a multivariate analysis demonstrated that the baseline absolute neutrophil count (ANC) and hemoglobin concentration were independent risk factors for grade 3 cytopenia. A total of 3 patients died early and were therefore excluded from the present study.

Furthermore, cell recovery was examined at day +28 after infusion; 21 patients (35%) did not recover from cytopenia and 39 patients (65%) recovered. A multivariate analysis demonstrated that the baseline ANC <2. 29 10 9 /l, baseline hemoglobin <114. 50 g/l and baseline IL-6 >21. 43 pg/l were independent risk factors affecting hemocyte recovery.

In conclusion, patients with relapsed and refractory B-NHL exhibited an increased incidence of grade 3 hematologic toxicity following CAR-T cell therapy, while baseline blood cell and IL-6 levels are independent risk factors for hemocyte recovery.